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Abstract 
 
Background 
Ventilator-associated pneumonia (VAP) is the most frequent 
infection  in  patients  intubated  for  longer  than  48  hours. 
There  is  a  great  interest  in  determining  the  factors 
influencing the outcome of VAP, as it may help in reducing 
the associated morbidity and mortality. This study aimed to 
determine  the  impact  of  appropriate  antibiotic  therapy 
based on endotracheal aspirate cultures on the outcome of 
VAP.  We  have  also  studied  the  other  factors  that  may 
influence the outcome of VAP. 
Method   
A cohort study was conducted in the intensive care units of 
a tertiary care hospital in South India over a period of 15 
months. 
The outcome of VAP was assessed by prolongation of the 
duration  of  mechanical  ventilation  and/  or  death  of  the 
patient. 
Results 
The  duration  of  mechanical  ventilation  was  significantly 
prolonged in patients with VAP (16.61 ± 8.2 d vs. 8.21 ± 5.9 
d,  P  <  0.0001).  VAP  patients  receiving  partially  or  totally 
inappropriate therapy (defined as lack of coverage of one or 
all the significant VAP pathogens) were at significantly high 
risk for death (Relative risk, 2.00; 95% confidence interval, 
1.14 to 3.52; P 0.0008). A delay of > 2 days in administering 
the first dose of appropriate antibiotic therapy significantly 
prolonged the duration of ventilation (P < 0.0001). Infection 
by multi-drug resistant pathogens, polymicrobial infection 
and time of onset of VAP did not have significant impact on 
the outcome of VAP. 
Conclusion 
Early  administration  of  appropriate  antibiotic  therapy, 
based on the antibiogram of the VAP pathogens identified 
by quantitative culture of endotracheal aspirate, could lead 
to  an  improved  outcome  of  patients  with  ventilator-
associated pneumonia. 
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Background 
Ventilator-associated pneumonia (VAP) is the most frequent 
intensive-care-unit  (ICU)-acquired  infection,  occurring  in 
patients intubated for longer than 48 hours. It is defined as 
pneumonia  occurring  more  than  48  hours  after  the 
initiation  of  endotracheal  intubation  and  mechanical 
ventilation (MV).
1 The incidence of VAP ranges from 6 to 
52%  and  can  reach  76%  in  some  specific  settings.
2  The 
mortality rates for VAP range from 20% to 76% in various 
studies.
3,4  In  a  retrospective  matched  cohort  study  using 
data from a large US inpatient database patients with VAP 
had a significantly prolonged duration of MV (14.3 days vs. 
4.7 days), ICU stay (11.7 days vs. 5.6 days), and hospital stay 
(25.5 days vs. 14.0 days).
5 
 
Because  of  the  large  disease  burden  and  the  resultant 
attributable  morbidity  and  mortality,  there  is  a  great 
interest in determining the factors influencing the outcome 
of  VAP,  which  may  help  in  reducing  the  morbidity  and 
mortality associated with this complication.
6  
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Although  empirical  administration  of  broad-spectrum 
antibiotics  decreases  the  risk  of  early-onset  VAP  due  to 
antibiotic susceptible bacteria, it predisposes to subsequent 
colonisation  and  infection  with  multidrug-resistant  (MDR) 
pathogens resulting in late-onset VAP.
3,4,7 
 
Therefore, this study was aimed at determining the impact 
of  appropriate  antibiotic  therapy  (based  on  endotracheal 
aspirate  cultures)  on  the  outcome  of  VAP.  We  have  also 
studied the other factors that may potentially influence the 
outcome of VAP. 
 
Method 
Setting and subjects 
A  cohort  study  was  conducted  in  the  departments  of 
Microbiology, Medicine and Anesthesiology & Critical Care 
of a tertiary care hospital.  During a period of 15  months 
(October 2006 to December 2007), all the adult patients on 
mechanical  ventilation  (MV)  for  >  48  hours  in  Medicine 
Intensive Care Unit (MICU) and Critical Care Unit (CCU) were 
included in this study. Patients with pneumonia prior to MV 
or within 48h of MV were excluded. Endotracheal aspirate 
cultures were done on the first and second day of MV to 
detect pneumonia prior to MV. 
 
Study design and data collection 
All the patients included in this study were monitored at 
frequent intervals (every third day) for the development of 
VAP using clinical and microbiological criteria until discharge 
or death. The relevant data such as age, gender, primary 
diagnosis, details of antibiotic therapy was recorded from 
medical records, bedside flow sheets, radiographic reports, 
and reports of microbiological studies of the patients. 
 
Definitions 
VAP was diagnosed in those patients who fulfilled both the 
clinical  and  microbiological  criteria.  The  criteria  were: 
Clinical criteria - Modified clinical pulmonary infection score 
(CPIS) > 6 (Table 1);
8 Microbiological criteria - Positive Gram 
stain (>10 Polymorphonuclear cells/ low power field and ≥ 1 
bacteria/ oil immersion field with or without presence of 
intracellular  bacteria)  and  quantitative  endotracheal 
aspirate culture showing ≥ 10
5 cfu/ ml.
2,9,10 VAP occurring 
within the first four days of MV was classified as early onset 
and VAP developing five or more days after initiation of MV 
was classified as late onset. 
 
The  quantitative  culture  results  were  informed  to  the 
treating  physicians  and  they  were  not  blinded,  as  the 
culture  results  might  aid  them  in  choosing  appropriate 
antibiotics  for  the  patients.  However,  the  choice  of 
antibiotics  for  the  treatment  of  VAP  patients  was  left  to 
their discretion. The physicians treated the patients on an 
individual  basis  using  a  combination  of  the  American 
Thoracic  Society  (ATS)  strategy,  surveillance  cultures, 
presence  of  risk  factors  for  MDR  pathogens,  and  their 
knowledge of the local microbial flora in the ICU and their 
antibiograms.  
 
Appropriate  therapy  was  defined  as  coverage  of  all  the 
significant  VAP  pathogens  (≥  10
5  cfu/  ml)  isolated  from 
endotracheal  aspirate,  by  the  antimicrobial  therapy 
administered  at  the  onset  of  VAP,  determined  by  the 
sensitivity  pattern  of  the  isolate.  Partially  inappropriate 
therapy  was  defined  as  lack  of  coverage  of  one  of  the 
significant  VAP  pathogens  (≥  10
5  cfu/  ml)  isolated  from 
endotracheal  aspirate,  by  the  antimicrobial  therapy 
administered at the onset of VAP, based on the sensitivity 
pattern of the isolate. Inappropriate therapy was defined as 
lack  of  antibiotic  coverage  of  all  the  significant  VAP 
pathogens  (≥  10
5  cfu/  ml)  isolated  from  endotracheal 
aspirate, based on the sensitivity pattern of the isolate. 
 
Impact  of  various  factors  on  the  outcome  of  VAP  was 
assessed  by  prolongation  of  the  duration  of  MV  and/  or 
death of the patient. 
 
Ethics 
This  study  was  approved  by  the  institute  research  and 
ethical  committees  and  informed  consent  was  obtained 
from the patient’s next of kin.  
 
Statistics 
Results were expressed as mean± SD. The chi-square test or 
Fisher’s exact test was used to compare patients without 
VAP to patients with VAP. Univariate analysis was used to 
compare the variables for the outcome groups of interest 
(patients  with  VAP  vs.  patients  without  VAP,  etc),  using 
statistics  software  (SPSS  16.0,  SPSS  Inc,  Chicago,  Illinois). 
Comparisons  were  unpaired  and  all  tests  of  significance 
were 2-tailed. Continuous  variables were compared using 
Student’s  t-test  for  normally  distributed  variables.  All  P 
values < 0.05 were considered statistically significant.  
 
Results 
Over  the  15-month  study  period  (October  2006  to 
December  2007), a total of  200 patients admitted to the 
ICUs  were  prospectively  evaluated.  Of  these  patients,  36 
(18%)  developed  VAP  during  their  ICU  stay.  Twenty-one 
patients (58.3%) had late-onset VAP, while 15 (41.7%) had 
early-onset VAP. The characteristics of the patients with and 
without VAP are summarised in Table 2.  
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Pseudomonas  aeruginosa  (21.3%)  and  Acinetobacter 
baumannii (21.3%) were the most common Gram negative 
bacteria  associated  with  VAP  and  Staphylococcus  aureus 
(14.9%)  was  the  most  common  Gram  positive  bacteria 
among patients with VAP. In 10 (27.8%) VAP cases, more 
than one pathogen was isolated. Acinetobacter baumannii 
was  the  most  common  VAP  pathogen  associated  with 
mortality,  accounting  for  37.5%  of  deaths.  Pseudomonas 
aeruginosa,  Providencia  spp.,  MRSA,  Candida  spp.  (Non-
albicans), Staphylococcus aureus were the other pathogens 
associated with mortality. Of the 36 patients with VAP, 10 
(27.8%)  had  polymicrobial  infection.  Twenty-nine  patients 
were  infected  with  MDR  pathogen,  while  seven  were 
infected  with  other  micro-organisms.
 
 
Table 1: Modified Clinical Pulmonary Infection Score (CPIS)* 
CPIS points  0  1  2 
Temperature (
oC)  ≥ 36.5 and ≤ 38.4  ≥ 38.5 and ≤ 38.9  ≥ 39 or ≤ 36 
Leucocyte count (per mm
3)  4,000 - 11,000  < 4,000 or > 11,000  < 4,000 or > 11,000 
Tracheal secretions  Rare  Abundant  Abundant + Purulent 
PaO2/ FiO2 mm Hg  > 240 or ARDS  -  ≤ 240 and no ARDS 
Chest radiograph  No infiltrate  Diffuse infiltrate  Localised infiltrate 
 
Culture of tracheal aspirate 
 
Light  growth  or  no 
growth 
 
Moderate  or  heavy 
growth  of    pathogenic 
bacteria 
 
 
 
Moderate  or  heavy 
growth  of    pathogenic 
bacteria 
and  presence  of  the 
same bacteria in Gram 
stain 
* Modified from Pugin et al
8 
 
Table 2: Characteristics of the VAP patients 
Parameter                      Non-VAP 
(n = 164) 
VAP 
(n = 36) 
P value (2-tailed) 
Age (mean ± SD)  36.8 ± 16.3  41.4 ± 14.7  0.17 
Gender   
95 (57.9%) 
69 (42.1%) 
 
24 (66.7%) 
12 (33.3%) 
 
0.43 
  Male 
Female 
Duration of MV  8.21 ± 5.9 d  16.61 ± 8.2 d   < 0.00 
Mortality  20.5%  18.2%   
 
 
Impact of VAP on outcome 
The duration of MV was significantly longer among patients 
who suffered from VAP (16.61 ± 8.2 d vs. 8.21 ± 5.9 d, P < 
0.0001). On an average there was about two times increase 
in the duration of the ICU stay among patients with VAP 
compared to those without VAP (16.97 ± 8.6 d vs. 8.50 ± 6.1 
d,  P  <  0.0001).  There  was  no  statistically  significant 
difference in mortality between VAP and non-VAP groups 
(RR, 0.89; 95% CI, 0.40 to 1.95; P 0.9486).  
 
Factors influencing outcome of VAP 
Inappropriate therapy was identified as the only significant 
factor influencing the outcome of the patients with VAP by 
univariate analysis (Table 3).  
 
Impact  of  treatment  on  outcome  Out  of  the  36  VAP 
patients, 24 (66.7%) received appropriate therapy based on 
the  antibiotic  susceptibility  pattern  of  the  causative 
organism,  while  seven  (19.4%)  received  partially 
inappropriate  therapy  and  five  (13.9%)  received  totally 
inappropriate  therapy.  VAP  patients  receiving  partially  or 
totally inappropriate therapy were significantly at high risk 
for death (RR, 2.00; 95% CI, 1.14 to 3.52; P 0.0008) (Table 3). 
There  was  a  significant  prolongation  of  MV  of  the  VAP 
patients with a time to first dose of appropriate antibiotic 
more than two days compared to those with a time to first 
dose  of  appropriate  antibiotic  ≤  2  days  (19.29 ﾱ 7.2 d  vs. 
9.43  ± 3.0 d, P < 0.0001). However, there was no difference 
in the mortality of the VAP patients on the basis of the time 
to  first  dose  of  appropriate  antibiotic,  as  all  the  patients 
who  received  appropriate  antibiotic  therapy  recovered 
successfully irrespective of the time of administration.  
  Australasian Medical Journal [AMJ 2012, 5, 2, 135-140] 
 
 
138 
Impact  of  polymicrobial  VAP  There  was  no  significant 
difference  in  the  duration  of  MV  between  polymicrobial 
VAP and monomicrobial VAP (18.00 ± 8.69 d vs. 16.17 ± 8.34 
d, P 0.572). There was no significant increase in mortality in 
polymicrobial  VAP  compared  to  monomicrobial  VAP  (RR, 
1.15; 95% CI, 0.25 to 5.30; P 1.000) (Table 3). 
 
Impact of time of onset of VAP There was no statistically 
significant difference in the duration of MV between early 
onset and late onset VAP (16.07 ± 9.2 d vs. 17.21 ± 7.9 d, P 
0.705).  There  was  no  statistically  significant  difference  in 
the mortality of early onset and late onset VAP (Two-tailed 
P value is 1.000) (Table 3). 
 
Table 3: Impact of different factors on outcome of VAP 
S. No.  Factor  Outcome  Relative risk (95% 
confidence limits) 
P value 
Death 
(n = 6) (%) 
Recovery 
(n = 27) 
(%) 
1.    Partially  or  totally 
inappropriate therapy 
* 
6 (100)  6 (22.2)  Infinity  0.00 
2.    Polymicrobial 
†  2 (33.3)  8 (29.6)  1.15 (0.25 to 5.30)  1.00 
3.    Late onset VAP 
‡  3 (50.0)  16 (59.3)  0.74 (0.17 to 3.12)  1.00 
4.    MDR pathogens  4 (66.7)  23 (85.2)  0.44 (0.10 to 1.89)  0.29 
VAP – Ventilator-associated pneumonia; MDR – Multi-drug resistant 
* - Three VAP patients who received appropriate therapy left against medical advice. 
† - Three VAP patients with monomicrobial VAP left against medical advice and their outcome was not known.  
‡ - One early-onset and two late-onset VAP patients left against medical advice (AMA) 
 
 
Impact of MDR pathogens 
There  was  a  significant  increase  in  the  duration  of  MV 
among  the  VAP  patients  infected  with  MDR  pathogens 
compared  to  those  infected  with  other  micro-organisms 
(18.04 ± 8.4 d vs. 10.83 ± 5.0 d, P 0.0378). There was no 
statistically  significant  difference  in  the  mortality  of  VAP 
caused  by  MDR  pathogens  and  others  (RR,  0.44;  95%  CI, 
0.10 to 1.89; P 0.2954) (Table 3). 
 
Impact of the treating physician 
As  the  choice  of  antibiotics  for  the  treatment  of  VAP 
patients  was  left  to  the  discretion  of  the  attending 
physician, the results of the mortality rate and duration of 
mechanical  ventilation  of  the  patients  could  have  been 
confounded  by  the  variable  of  attending  physician. 
However, we have not studied the impact of the treating 
physician on the outcome of VAP. 
 
Discussion 
VAP continues to be an important challenge to the critical 
care  physician  and  is  a  common  nosocomial  infection 
occurring in mechanically ventilated patients. In our study 
27.8% (10 out of 36) of the VAP cases were polymicrobial, 
which is consistent with other reports.
1,12 
 
The  majority  of  the  VAP  patients  (66.7%)  in  our  study 
received  appropriate  therapy  based  on  the  antibiotic 
susceptibility  pattern  of  the  causative  organism,  while 
19.4% and 13.9% received partially inappropriate or totally 
inappropriate  therapy  respectively.  Most  of  the  patients, 
who  were  on  inappropriate  therapy,  had  multi-drug 
resistant pathogens which were susceptible only to colistin. 
As many of these critically ill patients did not show good 
renal function, colistin could not be administered to these 
individuals. In some patients, Candida albicans was isolated 
along  with  other  bacterial  isolates.  In  these  patients,  the 
Candida albicans was considered to be a coloniser and only 
antibacterial  treatment  was  initiated,  which  resulted  in 
partially inappropriate treatment. Similarly, in a few cases, 
when  multiple  bacterial  isolates  were  obtained  from 
quantitative EA culture, some of them were considered as 
colonisers by the treating physicians, which had resulted in 
partially inappropriate therapy. 
 
VAP  patients  receiving  partially  or  totally  inappropriate 
therapy were found to be significantly at high risk for death. 
But  one  patient  with  VAP  due  to  a  non-MBL  producing 
Pseudomonas aeruginosa, resistant to meropenem by Kirby 
Bauer  disc  diffusion  method,  had  recovered  despite 
receiving  inappropriate  therapy.  Later  when  the  MIC  was 
determined for that isolate, it had a MIC of 1 µg/ ml, which 
was  within  the  susceptible  range.  Therefore,  that  isolate 
was  actually  susceptible  to  meropenem  despite  being 
labelled as resistant by Kirby Bauer disc diffusion method 
and so the patient had responded to the treatment.  
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Another five VAP patients had recovered despite receiving 
partially  inappropriate  therapy.  Those  patients  had 
polymicrobial  infection  and  had  received  appropriate 
therapy  for  only  one  of  the  multiple  micro-organisms 
isolated by quantitative culture. One reason for response to 
a  partially  inappropriate  therapy  could  be  that  only  one 
isolate which was treated with appropriate antibiotic was a 
true  pathogen,  while  the  other  isolates  could  have  been 
colonisers  and  falsely  identified  as  pathogens  by 
quantitative culture. Quantitative culture has been shown 
to  have  only  85%  specificity  which  supports  the  above 
hypothesis.
2 Moreover the in vitro susceptibility testing may 
not  accurately  predict  the  susceptibility  of  the  micro-
organism in vivo, which could be the other reason for the 
recovery  of  the  patients  despite  partially  inappropriate 
therapy. 
 
In our study, we observed that a delay of more than two 
days in administering the first dose of appropriate antibiotic 
therapy  significantly  prolonged  the  duration  of  MV  in 
patients with VAP. Similarly, in a study by Luna et al, the 
mortality rate of the patients with a delay in the initiation of 
the  appropriate  therapy  was  63.5%,  compared  to  a 
mortality  rate  of  29.2%  in  the  group  which  received 
appropriate  therapy  without  any  delay.
6  Therefore,  early 
administration  of  appropriate  therapy  is  important  to 
prevent undue prolongation of MV and reduce the mortality 
rate in patients with VAP. 
 
The duration of MV was significantly longer among patients 
who suffered VAP. The prolonged duration of MV and ICU 
stay underscore the significant financial burden imposed by 
the  development  of  VAP.  There  was  no  statistically 
significant  difference  in  mortality  between  VAP  and  non-
VAP groups in this study. Multivariate analyses conducted 
to evaluate the independent role played by VAP in inducing 
death  failed  to  identify  VAP  as  a  variable  independently 
associated with mortality in two studies.
4 
 
There was no significant difference in the duration of MV 
and outcome of polymicrobial VAP and monomicrobial VAP. 
Combes  et  al  also  observed  that  the  epidemiology  and 
outcomes of patients with monomicrobial and polymicrobial 
VAP did not differ significantly.
13  
 
The duration of MV and outcome of early onset and late 
onset VAP also did not differ significantly. Late-onset VAP, 
caused  by  MDR  pathogens  is  usually  associated  with 
increased morbidity and mortality.
14 In this study many of 
the early onset VAP cases had the risk factors for infection 
with  MDR  pathogens  like  prior  antibiotic  therapy  and 
current hospitalisation for five days or more. That could be 
the reason for the almost similar outcome of late onset and 
early onset VAP. The ATS guidelines also support the same 
reasoning by suggesting that patients with early-onset VAP 
who have received prior antibiotics or who have had prior 
hospitalisation within the past 90 days behave similarly to 
patients with late-onset VAP.
14  
 
In  this  study,  Acinetobacter  baumannii  was  the  most 
common  VAP  pathogen  associated  with  mortality, 
accounting  for  37.5%  of  deaths.  However,  no  significant 
increase  in  the  mortality  rate  was  observed  in  patients 
infected by MDR pathogens compared to those infected by 
other pathogens. In two different studies Pseudomonas or 
Acinetobacter  pneumonia  was  associated  with  high 
mortality  rates  of  65%  and  87%  which  was  significantly 
more  compared  with  31–55%  for  VAP  due  to  other 
microbes.
4  Similarly  in  another  study,  methicillin-resistant 
Staphylococcus  aureus  (MRSA)  was  associated  with  86% 
mortality directly attributable to pneumonia, compared to  
12% mortality rate with methicillin-sensitive Staphylococcus 
aureus  (MSSA).
15  The  reason  for  the  discordant  results 
between our study and others could be the high mortality 
rate  attributable  to  inappropriate  therapy  in  patients 
infected with non-MDR pathogens in our study. However, 
we noted a significant increase in the duration of MV and 
hospital  stay  in  patients  infected  by  MDR  pathogens.  A 
recent study has shown that the increased mortality of VAP 
caused by MDR as compared with non-MDR pathogens was 
attributable to more severe comorbidity before VAP.
16 
 
Conclusion 
To conclude, use of appropriate antibiotic therapy is a major 
prognostic factor for patients with VAP. Early administration 
of  appropriate  therapy,  based  on  the  antibiogram  of  the 
VAP  pathogens  identified  by  quantitative  culture  of 
endotracheal aspirate could lead to an improved outcome 
of  patients  with  ventilator-associated  pneumonia. 
Appropriate broad-spectrum antibiotics should be used for 
treatment of multi-drug resistant pathogens to reduce the 
mortality. 
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